CD226 Antikörper (PE)

Produktnummer ABIN2663188

Der Maus Monoklonal Anti-CD226-Antikörper wurde für FACS und ICFC validiert. Er ist geeignet, CD226 in Proben von Human zu detektieren.

Kurzübersicht für CD226 Antikörper (PE) (ABIN2663188)

Target: CD226

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser CD226 Antikörper ist konjugiert mit PE

Applikation: Flow Cytometry (FACS), Intracellular Flow Cytometry (ICFC)

Klon: TX25

Produktdetails anti-CD226 Antikörper (PE)

Aufreinigung: The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and unconjugated antibody.

Isotyp: IgG1 kappa

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide and 0.2 % (w/v) BSA .

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Protect from prolonged exposure to light. Do not freeze.

Lagerung: 4 °C

Informationen zur Lagerung: The antibody solution should be stored undiluted between 2°C and 8°C.

Details zu CD226

Target: CD226

Andere Bezeichnung: CD226

Hintergrund: DNAM-1 (CD226) is a ~65 kD glycoprotein expressed on cell surface of T cells, NK cells, monocytes/macrophages, platelets and megakaryocytes and a subset of B cells and a member of the immunoglobulin (Ig)-superfamily containing 2 Ig-like domains of the V-set. The ligands for CD226 are the poliovirus receptor (CD155) and its family member nectin-2 (CD112), which are broadly expressed on epithelial, endothelial and neuronal cells. CD226 is physically associated with LFA-1 in NK cells and activated T cells, and involved in LFA-1-mediated signaling.

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints